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Inflammatory bowel disease (IBD) is characterized by
dysregulated intestinal immune homeostasis and
cytokine secretion. Multiple loci are associated with
IBD, but a functional explanation is missing for
most. Here we found that pattern-recognition
receptor (PRR)-induced cytokine secretion was
diminished in human monocyte-derived dendritic
cells (MDDC) from rs7282490 ICOSLG GG risk
carriers. Homotypic interactions between the costi-
mulatory molecule ICOS and the ICOS ligand on
MDDCs amplified nucleotide-binding oligomeriza-
tion domain 2 (NOD2)-initiated cytokine secretion.
This amplification required arginine residues in the
ICOSL cytoplasmic tail that recruited the adaptor
protein RACK1 and the kinases PKC and JNK leading
to PKC, MAPK, and NF-kB activation. MDDC from
rs7282490 GG risk-carriers had reduced ICOSL
expression and PRR-initiated signaling and this
loss-of-function ICOSLG risk allele associated with
an ileal Crohn’s disease phenotype, similar to
polymorphisms in NOD2. Taken together, ICOSL
amplifies PRR-initiated outcomes, which might
contribute to immune homeostasis.
INTRODUCTION
Inflammatory bowel disease (IBD) is characterized by dysregu-
lated intestinal immune homeostasis and cytokine production.
Host-microbial interactions are initially mediated by pattern-
recognition receptors (PRRs); either loss-of-function or gain-of-
function in PRR-mediated signaling and downstream outcomes
can be associated with intestinal inflammation (Abraham and
Medzhitov, 2011). For example, a loss in PRR pathways (e.g.,
the adaptor protein MyD88- or Toll-like receptor 5 [TLR5]-defi-
cient mice) (Rakoff-Nahoum et al., 2004; Vijay-Kumar et al.,
2007) or a gain in PRR signaling (e.g., IRAK-M- or A20-deficient
mice) (Biswas et al., 2011; Hammer et al., 2011) can result in an
increased susceptibility to intestinal inflammation. A key
role for host-microbial interactions is further highlighted by
Crohn’s disease (CD)-associated NOD2 polymorphisms result-
ing in decreased nucleotide-binding oligomerization domain 2734 Immunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc.(NOD2)-dependent signaling. TheseNOD2 polymorphisms likely
increase risk for CD throughmultiple mechanisms (Abraham and
Cho, 2009; Abraham andMedzhitov, 2011). In the intestinal envi-
ronment, multiple other PRRs are activated and the outcomes of
their activation might be modulated by additional IBD risk loci.
Although a number of loci have now been associated with IBD
(Jostins et al., 2012), altered functions for the vast majority of
these loci are unknown. One such region is at chromosome
21q22, encompassing the ICOSLG gene. ICOSLG region poly-
morphisms are associated with various immune-mediated dis-
eases, including IBD (Franke et al., 2010; Jostins et al., 2012)
and celiac disease (Dubois et al., 2010). Inducible T cell costimu-
lator ligand (ICOSL), expressed on antigen-presenting cells
(APC), interacts with ICOS on T cells (Ling et al., 2000), thereby
contributing to T cell activation and differentiation (Dong et al.,
2001; Hutloff et al., 1999; Yoshinaga et al., 1999). Consistently,
ICOS- and ICOSL-deficient mice display a similar phenotype,
characterized by dysregulated T cell polarization and B cell im-
munity (Sharpe, 2009; Simpson et al., 2010). Unlike the well-
investigated role of ICOS signaling in adaptive immunity, how
ICOSL signals in myeloid cells is poorly understood. ICOS-Ig
treatment of mouse dendritic cells (DCs) results in p38
activation and interleukin-6 (IL-6) induction (Tang et al., 2009).
However, additional ICOSL-initiated signaling pathways and
the consequences of this signaling in DCs are unclear. Moreover,
a necessity for ICOSL signaling in PRR-initiated cytokine
induction has not been described.
In this study, we identified a role for ICOSL-initiated signaling
in PRR-mediated responses in primary human DCs. ICOS was
found to be expressed on monocyte-derived DCs (MDDCs), as
well as on intestinal myeloid-derived cells, and ICOS:ICOSL
interactions and downstream ICOSL-initiated signaling were
required for amplification of PRR-induced cytokines. Upon stim-
ulation with ICOS, ICOSL recruited protein kinase C (PKC), re-
ceptor for activated C kinase 1 (RACK1), and c-Jun N-terminal
kinase (JNK) to form amultiprotein complex that amplifies down-
stream signaling and cytokine secretion. MDDCs from ICOSLG
region rs7282490 homozygous carriers of the IBD disease-risk
allele (G) had reduced basal and PRR-induced ICOSL expres-
sion, decreased signaling in response to PRR and ICOSL stimu-
lation, and decreased PRR-induced cytokine secretion relative
to AA carriers. Finally, we found the loss-of-function ICOSLG
rs7282490 risk allele leads to an ileal-associated CD phenotype
that is similarly associated with loss-of-function NOD2 polymor-
phisms. Taken together, we establish loss-of-function conse-
quences for the rs7282490 risk polymorphism in the ICOSLG
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Figure 1. MDDCs from GG Carriers of the CD-Risk-Associated rs7282490 ICOSLG Region Polymorphism Have Decreased Cytokine Secre-
tion upon PRR Stimulation Relative to AA Carriers
Human MDDCs (n = 100) were stimulated for 24 hr with (A) 1, 10, or 100 mg/ml of MDP or (B) 1, 10, or 100 mg/ml of Pam3Cys. MDDCs (n = 98) were stimulated for
24 hr with 1 mg/ml MDP (NOD2 ligand) and 1 mg/ml Pam3Cys (TLR2 ligand), 0.1 mg/ml polyI:C (TLR3 ligand), 0.01 mg/ml lipid A (TLR4 ligand), 0.5 ng/ml flagellin
(TLR5 ligand), 0.1 mg/ml CL097 (TLR7 ligand), or 0.1 mg/ml CpGDNA (TLR9 ligand) for 24 hr (C) alone or (D) in combination. The data are represented as fold IL-1b
induction (log2 transformed) upon PRR stimulation stratified on the rs7282490 genotype + SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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amplification of PRR-induced cytokines.
RESULTS
MDDC from CD-Risk-Associated ICOSLG Carriers
Demonstrate Decreased PRR-Induced Cytokine
Secretion
Given that lipopolysaccharide (LPS) upregulates ICOSL expres-
sion on macrophages (Aicher et al., 2000), ICOSLG region poly-
morphisms are associated with IBD (Franke et al., 2010; Jostins
et al., 2012), and PRRs play a critical role in proper cytokine regu-
lation in the intestine, we asked whether ICOSL contributes to
PRR-induced cytokine secretion in human MDDCs. We first
asked whether the rs7282490 polymorphism downstream of
the ICOSLG gene, and the most significantly IBD-associated
polymorphism in the region (Jostins et al., 2012), might modulate
these effects. We initially examined NOD2-induced cytokine
secretion given the importance of NOD2 polymorphisms in CD
(Abraham and Cho, 2009). We utilized muramyl dipeptide
(MDP), the minimal bacterial peptidoglycan component specif-
ically activating NOD2 (Girardin et al., 2003; Hedl and Abraham,
2011a, 2012; Hedl et al., 2007; Inohara et al., 2003). MDDCs from
100 healthy individuals were stimulated with increasing concen-
trations of MDP, and interleukin-1b (IL-1b) secretion was exam-
ined because of its role in amplifying PRR-mediated responses
in humanmyeloid cells (Hedl and Abraham, 2011a) and high cor-
relation with multiple other cytokines (Hedl and Abraham, 2012).
We found less NOD2-induced IL-1b protein (log2 transformed) in
MDDCs from rs7282490 GG risk carriers compared to GA and
AA carriers (Figure 1A). Although the inhibitory effect of the
rs7282490 GG polymorphism was seen at all three doses, it
was most prominent at the lowest MDP concentration. Thegram-positive bacterial cell wall contains both NOD2 and TLR2
ligands, and MDDCs from rs7282490 GG risk carriers also
demonstrated decreased TLR2-mediated IL-1b secretion rela-
tive to AA carriers (Figure 1B). CD is associated with dysregu-
lated responses to bacteria, and bacteria activate multiple PRR
in addition to NOD2 and TLR2. Furthermore, NOD2 synergizes
with TLRs to induce more robust cytokine secretion (Li et al.,
2004; Netea et al., 2005). Therefore, we investigated whether
the rs7282490 polymorphism affects cytokine secretion by mul-
tiple PRR in a separate cohort of 98 healthy individuals. MDDCs
from rs7282490 GG risk carriers secreted decreased amounts of
IL-1b relative to GA and AA carriers after stimulation of TLR2,
TLR3, TLR4, TLR5, TLR7, and TLR9 alone (Figure 1C) or in com-
bination (Figure 1D) with NOD2. A similar decrease in tumor
necrosis factor alpha (TNF-a) and IL-10 was observed from
rs7282490 carrier MDDC (see Figure S1 available online). Taken
together, our results show that the rs7282490 IBD-associated
risk polymorphism in the ICOSLG region reduces PRR-initiated
cytokine secretion.
Human MDDCs and Intestinal Myeloid Cells Express
ICOS, and MDDCs Upregulate ICOSL upon NOD2
Stimulation
Given the rs7282490 genotype-dependent effects on cytokine
secretion in MDDC, we hypothesized that both ICOSL and
its binding partner, ICOS, are expressed on primary human
MDDC, allowing for ICOS:ICOSL engagement to promote cyto-
kine secretion through homotypic DC interactions. Previous
studies did not detect ICOS expression in mouse monocytes
or dendritic cells (Hutloff et al., 1999). ICOS was not present on
human monocytes (Figure 2A), but was expressed by MDDCs
at steady state (Figure 2A) and after MDP stimulation (data not
shown). Specificity of the anti-ICOS antibody was demonstratedImmunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc. 735
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Figure 2. Human MDDCs and Intestinal Myeloid Cells Express ICOS and ICOSL Are Upregulated on MDDCs upon NOD2 Stimulation
(A) Humanmonocytes (solid line) (n = 8), MDDCs (n = 11), and resting and activated primary human T cells (n = 3) were stained for ICOS. A subset of MDDCs (n = 3)
from the total cohort were run side-by-side in the same experiment as the T cells; MFI values were similar between these cell subsets. Representative flow
cytometry plots with MFI values are shown. Summary graphs of ICOS expression + SEM.
(B) MDDCs were transfected with scrambled or ICOS siRNA for 48 hr. Left shows representative flow cytometry plots with ICOS MFI values. Right shows
summary graph of ICOS expression + SEM (n = 4).
(C) ICOS expression by immunoblot from two donors (clone ANC6C6-A3). Resting and activated primary human CD4+ T cells served as controls. The band
migrating between 22 and 27 kDa is consistent with the monomeric form of ICOS. GAPDH served as loading control.
(D) Intestinal lamina propria cells were isolated from noninflamed colonic resection specimens and gated on CD11c+CD3 cells. Left shows representative flow
cytometry plots with ICOS MFI values. Right shows summary graph of ICOS expression + SEM (n = 5).
(E and F) MDDCs were transfected with scrambled or ICOSL siRNA for 48 hr. (E) Representative flow cytometry plot of ICOSL expression from one of seven
individuals with MFI as indicated. (F) ICOSL mRNA expression (n = 7) as assessed by RT-PCR.
(G and H) Human MDDCs (n = 8) were stimulated for (G) the indicated time points with 100 mg/ml MDP or (H) for 12 hr with indicated MDP doses. Left shows
representative flow cytometry plots with ICOSL MFI values. Right shows that summarized data are represented as the fold ICOSL induction normalized to
untreated cells (represented by the dotted line at 1) + SEM. (I) Shown is fold ICOSL mRNA expression (n = 8) normalized to untreated MDDCs (represented by the
dotted line at 1) + SEM. scr, scrambled; Tx, treatment. *p < 0.05; **p < 0.01; ***p < 0.001; y, p < 1x104; yy, p < 1x105.
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ICOSL Amplifies Innate Receptor-Mediated Signalingby decreased amounts of ICOS protein upon knockdown of
ICOS in MDDCs (Figure 2B). Moreover, ICOS expression on
MDDCs was within a range similar to that observed on activated
primary human T cells (Figure 2A). We further confirmed ICOS736 Immunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc.expression by flow cytometry by using a second anti-ICOS anti-
body (clone ISA-3; data not shown), and by immunoblot utilizing
two distinct antibodies (Figure 2C; Figure S2A). In addition to
studies on MDDC that were isolated at >95% purity with
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ICOSL Amplifies Innate Receptor-Mediated Signalingstandard procedures, MDDCs were isolated to >99.5% purity,
as assessed by flow cytometry andwere found to express similar
amounts of ICOS protein (Figure S2B) and RNA (Figure S2C). We
confirmed RNA purity by ensuring expression of the MDDC
marker CD11c, but not the T cell marker CD3, and further verified
ICOSL mRNA expression with the highly purified MDDCs
(Figure S2C). Small interfering RNA (siRNA) knockdown of
ICOS also reduced ICOS mRNA expression in the highly purified
MDDCs (Figure S2D). Finally, we examined ICOS expression on
intestinal myeloid cells. ICOS was expressed on CD11c+CD3
intestinal myeloid-derived cells in amounts comparable to
peripheral MDDCs (Figure 2D). In contrast, we did not observe
ICOS expression on ex vivo CD3+ T cells in uninflamed intestine
(data not shown), consistent with prior reports (Sato et al., 2004).
Because ICOS expression on peripheral monocyte-derived
macrophages was similar to MDDCs (data not shown), we also
examined CD33+ cells in the intestine; CD33 is used as a marker
of intestinal myeloid-derived cells, in particular macrophages
(Kamada et al., 2008; Rogler et al., 1998). ICOS was expressed
on CD33+ intestinal myeloid-derived cells to levels comparable
to MDDCs (data not shown).
ICOSL was also expressed by MDDCs (Figure 2E) and both
ICOSL protein and mRNA were reduced in response to ICOSL
siRNA-mediated knockdown (Figures 2E and 2F). Furthermore,
we found that ICOSL transcription and surface expression
increased upon NOD2 stimulation (Figures 2G–2I). Thus, in
addition to expressing ICOSL, MDDCs and intestinal DCs
express ICOS.
PRR Stimulation Induces ICOS-ICOSL Interactions on
MDDCs, which in Turn Amplifies Cytokine Secretion
We next asked whether ICOSL and ICOS contribute to PRR-
induced cytokine secretion. ICOSL expression was knocked
down by siRNA (Figure 2E and 2F) and NOD2-induced cytokine
secretion upon stimulation with 100 mg/ml MDP was examined
(Figure 3A). This MDP dose results in peak induction of ICOSL
expression (Figure 2H) and approximates amounts of muramic
acid in stool (Vavricka et al., 2004). Induction of the proinflamma-
tory cytokines TNF-a, IL-8, IL-1b, and IL-23, which are dysregu-
lated in CD (Abraham and Cho, 2009), and the anti-inflammatory
cytokine IL-10 in response to NOD2 stimulation was reduced
upon ICOSL silencing (Figure 3A). Silencing of ICOS (Figure 2B)
also decreased NOD2-induced cytokine secretion (Figure 3B).
These results were confirmed with three additional siRNAs
against each ICOSL and ICOS eliminating the possibility of off-
target effects (Figure S3A). We further ensured cell viability
was intact (Figure S3B) and that functional responseswere intact
upon stimulation through an alternative pathway utilizing dectin
ligands (Figure S3C). Similar data were obtained with ICOSL-
and ICOS-neutralizing antibodies (Figure S3D). Therefore, these
data demonstrate that both ICOS and ICOSL on MDDCs are
critical for optimal NOD2-mediated cytokine secretion.
We next asked whether NOD2-mediated cytokine induction in
MDDCs was regulated by ICOS- or ICOSL-initiated signaling.
We first stimulated cells with 1 mg/ml MDP, a dose that resulted
in low cytokine secretion (Figure 3C), and asked whether adding
soluble recombinant ICOSL or ICOS, respectively, enhances this
low cytokine secretion. Soluble ICOSL did not enhance the low
amounts of cytokine secreted by MDDC in response to 1 mg/mlMDP (Figure 3D). The soluble ICOSL was functional as it was
able to costimulate primary T cells (data not shown). In contrast,
soluble ICOS markedly enhanced NOD2-induced cytokine
secretion (Figures 3E and 3F). Notably, MDDC treatment with
ICOS alone induced low cytokine secretion (Figure 3E), indi-
cating that ICOSL-initiated signaling is sufficient for cytokine in-
duction. When ICOSL expression was silenced, ICOS treatment
failed to increase NOD2-mediated cytokine secretion, clearly
establishing ICOS-ICOSL interactions are required to enhance
NOD2-induced cytokine secretion (Figure S3E). The MDDCs
did not contain significant T cell contamination (ranging from
0.5%–5%). Moreover, resting T cells express very low amounts
of ICOS (Figures 2A and 2C). However, to ensure that amplifica-
tion of PRR-induced cytokine secretion by ICOSL was mediated
by ICOS on MDDCs rather than ICOS on T cells, we added
an increasing percentage (up to 10%) of purified, resting
T cells to MDDCs in which ICOS was silenced. This failed to in-
crease NOD2-mediated cytokine secretion, whereas addition
of MDDCs (up to 10%) rescued the enhanced cytokine secre-
tion; addition of intact MDDC to 50%almost completely restored
cytokines (Figure S3F). Therefore, in contrast to the low amount
of ICOS on resting T cells, ICOSonMDDCs is sufficient and func-
tional in mediating downstream outcomes. To further verify that
cell-derived ICOS can interact with ICOSL on MDDCs to
increase cytokine secretion, we confirmed that HeLa cells trans-
fected with ICOS (Figure S3G) enhanced MDP-induced cyto-
kines relative to empty vector (EV)-transfected cells (Figure S3F).
Soluble ICOS was similarly able to rescue NOD2-induced cyto-
kine secretion under conditions where ICOS expression in
MDDCs was reduced (Figure S3F). Nuocytes are another
ICOS-expressing population (Wong et al., 2012); however, these
were not present in our MDDC population, whereas we could
detect nuocytes in intestinal lamina propria cells (data not
shown). To further verify that the ICOS:ICOSL-mediated effects
inMDDCwere not contaminated with ICOS-expressing cell pop-
ulations, we confirmed the ability of ICOS:ICOSL to augment
MDP-induced cytokine secretion on highly purified MDDCs
(>99.5% purity as per cells examined in Figures S2B–S2D) (Fig-
ure S3H). Taken together, we establish that ICOS is expressed
on MDDCs and interacts with ICOSL to initiate ICOSL-mediated
signaling which, in turn, augments NOD2-induced cytokine
secretion from MDDCs.
ICOSL Signaling Enhances NOD2-Induced MAPK,
NF-kB, and PI3K Activation in Primary Human MDDCs
We next sought to define the signaling pathways activated upon
ICOSL stimulation onMDDCs. Previous studies have shown that
ERK, p38, and JNK contribute to cytokine secretion upon PRR,
including NOD2, stimulation (Hedl and Abraham, 2011a, 2012;
Kawai and Akira, 2010; Kobayashi et al., 2005; Park et al.,
2007; Pauleau and Murray, 2003; Vidal et al., 2001; Yang et al.,
2007). We therefore measured their activation after MDDCs
were treated with low dose MDP, ICOS, or combined MDP and
ICOS. Similar to the cytokine data (Figure 3E), ERK, p38, and
JNK were all activated by low-dose MDP or ICOS treatment
alone and activation was enhanced by combined ICOS and
MDP treatment (Figure S4A). We observed a similar pattern of
activation in the NF-kB pathway (Figure S4B), and the intermedi-
ates of the PI3K pathway Akt and mTOR (Figure S4C), which allImmunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc. 737
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Figure 3. ICOSL and ICOS Enhance NOD2-Induced MAPK, NF-kB, and PI3K Activation and Cytokine Secretion in Primary Human MDDCs
(A and B) MDDCs (n = 8) were transfected with scrambled, (A) ICOSL, or (B) ICOS siRNA and 48 hr later stimulated for 24 hr with 100 mg/ml of MDP. Shown are
cytokines in supernatants + SEM. Significance was calculated compared to scrambled siRNA transfected, MDP-treated cells. Similar results were observed in an
additional n = 4.
(C–F) MDDCs (n = 14–16) were left untreated or stimulated for 24 hr with (C) indicated doses of MDP, (D) 100 mg/ml recombinant ICOSL, or (E) 10 mg/ml re-
combinant ICOS alone or combined with 1 mg/ml MDP. Shown is cytokine concentration in supernatants + SEM or (F) synergy calculated as a fold increase of
cytokine levels upon combined ICOS andMDP treatment divided by the sum of the cytokine levels upon treatment with each stimulus alone + SEM. Stimulation of
cells with an IgG1 isotype control did not result in cytokine secretion (data not shown).
(G–I) MDDCs (n = 6–12) were transfected with scrambled or ICOSL siRNA. Forty-eight hr later, cells were stimulated for 15 min with 100 mg/ml MDP. Left shows
representative flow cytometry plots with MFI values for (G) phospho-ERK, -p38, and -JNK, (H) phospho-IkBa, or (I) phospho-Akt and phospho-p70S6K. Right
shows that summarized data are represented as the fold phosphoprotein induction normalized to untreated, scrambled siRNA transfected cells + SEM.
scr, scrambled, Tx, treatment; IC, ICOS; ICL, ICOSL. *p < 0.05; **p < 0.01; ***p < 0.001; y, p < 1x104; yy, p < 13 105. Lines over adjacent bars indicate identical p
values for these bars.
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Figure 4. ICOSL Is Required for Optimal Cytokine Secretion upon Stimulation of Multiple PRR
Human MDDCs (n = 8) were transfected with scrambled or ICOSL siRNA. Forty-eight hr later, cells were stimulated for 24 hr with 10 mg/ml Pam3Cys (TLR2),
100 mg/ml polyI:C (TLR3), 0.1 mg/ml lipid A (TLR4), 5 ng/ml flagellin (TLR5), or 10 mg/ml CpG DNA (TLR9). Cytokine concentrations in the supernatants are
shown + SEM. Significance was calculated compared to scrambled siRNA transfected, PRR-treated cells. We confirmed the results with TLR ligands in an
additional n = 4. Tx, treatment; scr, scrambled *p < 0.05; **p < 0.01; ***p < 0.001; y, p < 1x104; yy, p < 1 3 105.
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2012; Kobayashi et al., 2005). Taken together, ICOSL synergizes
with suboptimal NOD2 stimulation to increase activation of path-
ways critical for cytokine secretion, including the MAPK, NF-kB,
and PI3K signaling pathways.
Exogenous ICOS treatment was found to enhance cytokine-
activating signaling pathways induced by low-dose MDP (Fig-
ures S4A–S4C). We next asked whether endogenous ICOS:
ICOSL interactions were necessary for MAPK, NF-kB, and
PI3K pathway activation in response to MDP. We used
100 mg/ml of MDP, a dose that promotes increased ICOSL
expression (Figure 2H) and requires both ICOS and ICOSL for
optimal NOD2-initiated cytokine secretion (Figures 3A and 3B).
Silencing of ICOSL in MDDCs resulted in reduced activation of
ERK, p38, and JNK after NOD2 stimulation (Figure 3G), and
the phosphoflow data were confirmed by immunoblot (Figures
S4D). Similarly, activation of the NF-kB pathway (Figure 3H;
Figure S4E) and the PI3K pathway (Figure 3I) were attenuated
in these cells. Taken together, ICOSL is required for optimal
NOD2-initiated MAPK, NF-kB, and PI3K signaling in primary
human MDDCs. Having identified that ICOSL stimulation was
required for optimal signaling (Figures 3G–3I) and cytokine
induction (Figure 3A) upon NOD2 stimulation of MDDCs, we
next asked whether ICOSL contributed to cytokine induction
upon stimulation of other PRR. We observed that ICOSL was
required for optimal cytokine secretion upon TLR2, TLR3,
TLR4, TLR5, and TLR9 stimulation of human MDDCs (Figure 4).
PKCa and PKCb Are Required for Phosphorylation of
ICOSL and ICOSL-Mediated Cytokine Induction
Unlike the well-investigated signaling through ICOS in T cells,
ICOSL-initiated pathways are poorly understood. To better
dissect the mechanisms through which ICOSL activation regu-
lates PRR-induced signaling, we conducted an initial in silico
analysis and identified serines and threonines in the ICOSL cyto-
plasmic region thatmight serve as putative PKCphosphorylation
sites. To more clearly examine the role of PKCs in PRR signaling,
we first established that PKCswere activated after ICOS and low
dose (1 mg/ml) MDP treatment of MDDC, and that combined
treatment synergized to increase PKC activation (Figure S5A).
Moreover, we verified that upon 100 mg/ml MDP treatment,
knockdown of ICOSL impaired PKC activation (Figure S5B).
We then asked whether PKC activation functions upstream of
the signaling pathways activated upon ICOSL stimulation. PKCclasses include conventional PKCs (such as PKCa, PKCb, and
PKCg) and atypical PKCs (such as PKCz). Upon inhibition of con-
ventional PKCs and PKCz in ICOS-stimulated MDDCs, MAPK,
NF-kB, and PI3K signaling was attenuated (Figure S5C–S5E).
The results of the pharmacological inhibition were subsequently
confirmed with a siRNA approach presented below. Therefore,
PKCs are required for signaling downstream of ICOSL. As ICOSL
contains putative PKC phosphorylation sites, we next asked
whether ICOS treatment led to PKC-dependent phosphorylation
of ICOSL. Due to the cell number limitation of primary human
monocytes and large numbers of cells required for immunopre-
cipitation experiments, we addressed this question in the human
monocytic HL-60 cell line, which also upregulated ICOSL
expression after treatment with PRR ligands such as LPS (Fig-
ure S5F) and required ICOSL signaling for LPS-mediated cyto-
kine induction (Figure S5G). Low amounts of cytokine secretion
were observed after ICOS treatment, which was mediated by
ICOSL (Figure S5H). By using an antibody recognizing phos-
phorylated PKC consensus sites, we found that ICOS treatment
of HL-60 cells led to phosphorylation of PKC substrate motifs
on ICOSL-corresponding bands (Figure 5A). Ensembl analysis
(http://www.ensembl.org) identifies four human ICOSL isoforms,
the most common splice variants being the 52, 34, and 33 kDa
variants (Ling et al., 2001). We observed bands migrating at
the molecular weights corresponding to the sizes of these iso-
forms (Figure 5A). We next asked which PKCs were required
for phosphorylation of ICOSL. Conventional PKCs are critical
for ICOSL-initiated signaling (Figures S5C–S5E), and both
PKCa and PKCb, but not PKCg, are expressed in myeloid cells
(Webb et al., 2000) (data not shown). PKCa and PKCb knock-
down (Figures S5I and S5J) reduced both ICOS-induced ICOSL
phosphorylation in HL-60 cells and ICOSL-mediated cytokine
secretion in MDDC (Figures 5A and 5B). Thus after ICOS treat-
ment, ICOSL is phosphorylated on PKC substrate sites in a
PKCa- and PKCb-dependent manner, and PKCa and PKCb
activation is in turn required for ICOSL-mediated downstream
signaling and cytokine induction.
Arginine Residues in the ICOSL Cytoplasmic Tail Are
Required for Recruitment of Signaling Molecules
We next sought to define the mechanism through which ICOSL
signaling affects downstream outcomes and to define the struc-
tural requirements in ICOSL for these outcomes. The 34 kDa
ICOSL isoform has a short cytoplasmic tail with two highlyImmunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc. 739
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Figure 5. PKCa and PKCb Are Required for Phosphorylation of ICOSL and ICOSL-Mediated Cytokine Induction
(A) HL-60 cells were transfected with scrambled, PKCa, or PKCb siRNA as indicated and stimulated with 10 mg/ml ICOS for 15 min. Cell lysates were immu-
noprecipitated with anti-ICOSL antibody, and phosphorylation of PKC substrate motifs in ICOSL was assessed by immunoblot. GAPDH expression from total
lysates served as the loading control. Left shows two representative immunoblots. Right shows that summarized data (n = 6) are represented as the fold
phosphoprotein induction normalized to untreated, scrambled siRNA-transfected cells for each of the two bands visualized (representing distinct ICOSL
isoforms) + SEM.
(B) MDDCs (n = 8) were transfected with scrambled, PKCa, or PKCb siRNA and 48 hr later stimulated for 24 hr with 10 mg/ml ICOS. Cytokine concentrations in
supernatants are shown + SEM. scr, scrambled; IC, ICOS; p-, phospho-. *p < 0.05; **p < 0.01; ***p < 0.001; y, p < 1x104; yy, p < 1 3 105.
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residues (S285 and S293) of which only S285 is conserved
across several species (Figure 6A). Arginine residues can serve
as recruitment sites for PKC (Leventhal and Bertics, 1993). We
therefore constructed ICOSL mutants in which the arginines
and serines, alone or in combination, were replaced with ala-
nines. We also generated an ICOSL mutant without an intracel-
lular cytoplasmic tail in order to assess the importance of
signaling initiated by the cytoplasmic tail. We expressed each
of these ICOSL variants in HeLa cells, a cell line that did not
express detectable surface ICOSL, and observed equivalent
surface expression with each of the constructs in amounts com-
parable to MDDCs (Figure 6B).
After ICOS treatment, we observed phosphorylation of PKC
substrate motifs (with a phosphorylated band corresponding to
the 34 kDa ICOSL isoform) in cells expressing wild-type (WT)
ICOSL (Figure 6C). This phosphorylation was absent in the tail-
less, S285A, S285A and S293A, R278A, R280A, and R278A
and R280A mutants, but remained intact in S293A mutants (Fig-
ure 6C). Therefore, S285 is required for PKC substrate (serine)
phosphorylation of ICOSL, and each of the upstream arginines
is similarly required for this phosphorylation. We next asked
what the signaling events initiated by the ICOSL cytoplasmic
tail are that contribute to cytokine secretion. Conventional, acti-
vated PKCb can recruit the scaffolding protein RACK1 and JNK
resulting in c-Jun activation (Lo´pez-Bergami et al., 2005). RACK1
knockdown in primary MDDCs decreased ICOSL-induced cyto-
kine secretion (Figure S6A), suggesting a role for RACK1 in
ICOS:ICOSL outcomes. Similarly, JNK pathway activation is
required for NOD2-induced (Hedl and Abraham, 2012) and
ICOSL-induced cytokine secretion (data not shown) in primary740 Immunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc.myeloid cells. Upon ICOS treatment, PKCb, RACK1, and JNK
were each recruited to ICOSL; recruitment of these molecules
was absent in tailless, R278A, and R280A but intact in S285A
and S293A mutants (Figure 6C). These findings are consistent
with prior studies showing that arginine-containing peptides
are sufficient for recruitment of conventional PKC (Leventhal
and Bertics, 1993).
As the S285A ICOSL mutant resulted in a loss of PKC sub-
strate phosphorylation in ICOSL but did not affect PKCb,
RACK1, or JNK recruitment to ICOSL, we sought to define the
role of S285 in ICOSL-mediated outcomes. Phosphorylation of
PKC can modulate its ability to phosphorylate and activate
downstream substrates, such as JNK (Lo´pez-Bergami et al.,
2005). We therefore hypothesized that the phosphorylation of
S285 in ICOSL might contribute to optimal activation of the
PKCb and JNK recruited to ICOSL. In the ICOS-induced protein
complex associated with the S285A ICOSL mutant, there was
a 20%–30% decrease in phosphorylated PKCb and activation
of JNK as assessed by phosphorylation of its c-Jun substrate
(Figure 6D). Consistent with the failure to recruit PKCb and
JNK to the ICOSL tail, phospho-PKCb and phospho-c-Jun
were not detected in association with tailless, R278A, R280A
or R278A/R280A ICOSL mutants (Figure 6D). We further verified
the requirement for PKC activation in the phospho-c-Jun associ-
ated with ICOSL through both inhibition and knockdown of con-
ventional PKC (Figure 6E).
We next examined if the S285A, R278A or R280A ICOSL mu-
tations leading to phosphorylation defects of signaling mole-
cules within the ICOSL-associated complex also lead to cellular
signaling defects. ICOS-dependent phosphorylation of JNK (Fig-
ure S6B) and its substrate, c-Jun, (Figure 6F) was diminished in
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R278A and R280A ICOSL mutants. Similar results were
observed with activation of IkBa (Figure 6F). Tailless ICOSL
also resulted in a loss of ICOSL-initiated JNK and NF-kB
pathway activation (Figure 6F; Figure S6B). Taken together,
upon ICOS treatment, S285 in ICOSL is required for optimal
phosphorylation of proteins recruited to ICOSL. In contrast,
R278 and R280 are required for recruitment, and therefore
phosphorylation, of proteins associated with ICOSL, which in
turn, leads to activation of cytokine-inducing pathways after
ICOS:ICOSL interactions.
We next examined how the ICOSL mutants affect ICOS:
ICOSL-mediated cytokine induction and synergy with NOD2. In
HeLa cells transfected with WT NOD2 and ICOSL, IL-6 was
secreted after either MDP or ICOS treatment (Figure 6G), and
secretion was increased after combined MDP and ICOS treat-
ment (Figure 6G). This synergy was abolished if WT NOD2 was
coexpressedwith ICOSL lacking the cytoplasmic tail (Figure 6G).
Consistent with the recruitment of signaling complexes and
phosphokinase activation (Figures 6C and 6F), IL-6 secretion
was decreased in S285A ICOSL mutants after ICOS (Figure 6H,
left) or ICOS and MDP treatment (Figure 6H, right), and IL-6
secretion was abolished in R278A and R280A ICOSL mutants
upon ICOS treatment and dramatically attenuated upon com-
bined ICOS and MDP treatment (Figure 6H). The S285A and
S293A mutations combined did not further impair cytokine
secretion relative to S285A (Figure 6H), consistent with the failure
of this combined mutant to further attenuate ICOSL-initiated
signaling pathways (Figure 6F; Figure S6B). Similar results
were observed with IL-8 secretion (data not shown). Taken
together, the synergy in cytokine induction with NOD2 and
ICOS:ICOSL stimulation is modulated by conserved arginine
residues in the cytoplasmic tail of ICOSL, which recruit the
PKC-RACK1-JNK signaling complex.
The rs7282490 Risk G Allele in the ICOSLG Region Is
Associated with Decreased ICOSL Expression
We next sought to define the mechanism through which
the rs7282490 polymorphism regulates PRR-induced cytokine
secretion. Because rs7282490 is downstream of the ICOSLG
gene, we hypothesized that it might influence basal and/or
induced ICOSL expression. We therefore assessed ICOSL
expression in MDDC from AA, GA, and GG rs7282490 individ-
uals. MDDC from GG carriers expressed lower amounts of
ICOSL mRNA (Figure 7A) and protein (Figure 7B) than MDDCs
from AA individuals, whereas GA carriers showed an inter-
mediate ICOSL expression. MDP stimulation increases ICOSL
expression (Figures 2G–2I) and the difference in ICOSL expres-
sion between GC and AA carriers were more pronounced upon
MDP stimulation (Figures 7A and 7B). To better assess whether
the rs7282490 risk allele regulated ICOSL induction by MDP, we
reanalyzed the data by normalizing the amount of MDP-induced
ICOSL mRNA and protein to that present in unstimulated cells.
We found that NOD2-mediated ICOSL induction was clearly
lower in GG carriers relative to AA homozygotes (Figure 7C).
The expression of the 52 kDa, 34 kDa, and 33 kDa ICOSL iso-
forms underwent upregulation upon MDP treatment similar to
that observed when using primers detecting a site common to
all three ICOSL isoforms, with the maximum induction peak at4 hr (Figure 2G; Figure S7A). Furthermore, GG rs7282490 carriers
showed decreased expression of all three ICOSL isoforms in
untreated or MDP-treated MDDCs relative to AA carriers (data
not shown). Other genes in the region did not demonstrate
altered expression based on rs7282490 genotype (Figure S7B).
Moreover, knockdown of these genes (Figure S7C) did not
regulate NOD2-induced cytokine secretion (Figure S7D). To
determine whether the rs7282490 genotype, in turn, leads to dif-
ferences in signaling, we measured induction of ERK activation
in cells fromAA andGGhomozygotes, because these genotypes
showed the most dramatic differential in ICOSL expression
(Figures 7A–7C) and cytokine secretion (Figure 1). We found
less ERK activation in GG carriers after MDP, ICOS, and partic-
ularly combined MDP and ICOS treatment of MDDCs compared
to AA carriers (Figure 7D). Therefore, consistent with the
decreased cytokine production after PRR stimulation (Figure 1),
MDDCs from disease-risk rs7282490 GG carriers demonstrate
decreased basal and NOD2-induced ICOSL expression, as
well as decreased ICOSL-initiated signaling.
The rs7282490 Risk G Allele in the ICOSLG Region Is
Associated with Increased Likelihood of Ileal CD
CD carriers of NOD2 loss-of-function polymorphisms demon-
strate an increased ileal disease frequency (Figure 7E) (Abraham
and Cho, 2009). Because ICOSL was found to amplify NOD2-
initiated signaling and cytokine secretion (Figures 1, 3, 6,
and 7), we asked whether the CD risk loss-of-function G allele
at rs7282490 in the ICOSLG region also shows an increased ileal
distribution. We observed a higher frequency of the rs7282490 G
allele in ileal disease CD compared to colonic CD (Figure 7E).
Because GG carriers demonstrate decreased PRR-induced
cytokine secretion compared to AA and GA carriers, we exam-
ined a recessive inheritance model for ileal disease. Consistent
with the functional effects on cytokine secretion, we observed a
greater effect of the G allele on ileal location in the recessive
compared to the allelic inheritance model (Figure 7E).
DISCUSSION
Disease-associated polymorphisms represent important func-
tional perturbations that can define unexpected gene functions
in pathways fundamental to disease pathogenesis. In this study,
we found that ICOS:ICOSL signaling amplifies PRR-initiated
signaling and cytokine secretion by primary human MDDCs.
We identified that ICOS is expressed on MDDCs and intestinal
DCs, and that ICOS on MDDCs can interact with ICOSL on
MDDCs leading to ICOSL-initiated signaling. The ability of costi-
mulatory molecules to amplify PRR responses is relatively unex-
plored. We found that two arginines in the proximal cytoplasmic
tail of ICOSL are required for recruitment of PKCb, RACK1, and
JNK to ICOSL, which leads to activation of the proteins in this re-
cruited complex and subsequent activation of cellular signaling
and cytokine secretion. Given the impaired PRR-induced sig-
naling and cytokine secretion in the absence of ICOS, we
hypothesize that direct ICOS:ICOSL interactions lead to the
vast majority of the ICOSL cytoplasmic tail-associated events
during PRR stimulation. We found that MDDCs from IBD-
associated rs7282490 GG risk carriers in the ICOSLG region
show decreased basal and NOD2-induced ICOSL expression.Immunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc. 741
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Figure 6. Arginine Residues in the Proximal ICOSL Cytoplasmic Tail Are Required for the Recruitment of Signaling Intermediates Leading to
Cytokine Secretion
(A) Sequence alignments (CLUSTALW) of mammalian ICOSL cytoplasmic tail sequences and indicated mutated residues.
(B) EV, WT ICOSL, tailless, S285A, S293A, S285A and S293A, R278A, R280A or R278A, and R280A ICOSL mutants were transfected into HeLa cells. Surface
ICOSL expression was measured 24 hr later by flow cytometry. Expression was comparable to primary MDDCs (shown as control).
(C and D) HeLa cells were transfectedwithWT ICOSL or ICOSLmutants and stimulated with 10 mg/ml ICOS for 15min. Cell lysateswere immunoprecipitatedwith
anti-ICOSL antibody. (C) Phosphorylated PKC substrate, or PKCb, RACK-1, and JNK recruitment was assessed by immunoblot. (D) Phospho-PKCb and
phospho-Jun associated with ICOSL was assessed by immunoblot. Normalized densitometry measurements are shown above the gels. (E) HeLa cells were
transfected with WT ICOSL, and PKC was inhibited either through PKCb siRNA transfection at the same time or through 10 mMbisindolylmaleimide at the time of
(legend continued on next page)
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signaling, which reduced amplification of PRR signaling and
cytokine secretion (Figure S7E). Although MDDCs from the
rs7282490 risk carriers are only partially reduced in PRR-
induced cytokine secretion due to a relative decrease in ICOSL
expression, complete knockdown of ICOSL expression attenu-
ates PRR-induced cytokine secretion even at high doses of
PRR ligands. Similar to loss-of-function NOD2 risk individuals,
loss-of-function ICOSLG risk GG carriers exhibit increased as-
sociation with an ileal phenotype of CD.
Although inflammatory diseases are characterized by in-
creased cytokine production, multiple loss-of-function poly-
morphisms in genes participating in inflammatory-inducing
pathways within innate pathways are associated with CD
(Abraham and Cho, 2009). Similarly, mice deficient in genes
participating in innate response pathways (e.g., TLR5 [Vijay-
Kumar et al., 2007], MyD88 [Rakoff-Nahoum et al., 2004]) can
demonstrate inflammatory outcomes with enhanced colitis sus-
ceptibility, highlighting that proper initial innate responses are
required for intestinal immune homeostasis. Enhanced inflam-
mation in the context of loss-of-function in innate response
pathways can occur for various reasons, including a failure to
properly respond to or efficiently eliminate microbes (Feuillet
et al., 2006; Grainger et al., 2013; Naiki et al., 2005), which can
lead to inappropriately increased compensatory inflammatory
responses. NOD2 loss-of function polymorphisms and ICOSLG
rs7282490 represent two major IBD-risk polymorphisms result-
ing in reduced PRR-initiated cytokine secretion. Moreover, GG
rs7282490 carriers show reduced cytokine secretion upon
stimulation of a broad range of PRR, indicating that this poly-
morphism is both common and has global innate regulatory
consequences. A role for the costimulatory molecule ICOSL in
amplifying PRR-induced cytokine secretion on myeloid cells is
particularly relevant to IBD given that myeloid cells mediate early
microbial recognition in the intestine. Our findings identify a
critical role for the rs7282490 ICOSLG region polymorphism
associated with immune-mediated diseases in amplifying PRR-
initiated inflammatory signaling and cytokine secretion.
EXPERIMENTAL PROCEDURES
Recruitment and Genotyping
Informed consent was obtained per protocol approved by the institutional re-
view board at Yale University. For cell studies in healthy controls, we recruited
participants with no personal or family history of immune-mediated diseases,
including psoriasis, SLE, rheumatoid arthritis, multiple sclerosis, type I dia-
betes mellitus, CD, and ulcerative colitis, or a history of HIV. Due to the limita-
tion in primary human cells and the range of stimulation conditions we wishedICOS treatment. Cells were then treatedwith 10 mg/ml ICOS for 15min. Cell lysates
was assessed by immunoblot. (C–E) ICOSL expression from total lysates served
(F) HeLa cells were transfected with EV, WT ICOSL, or ICOSL mutants. Twenty-f
representative flow cytometry plots with MFI values. Bottom shows that summar
untreated, WT ICOSL transfected cells + SEM. Significance is compared to ICO
(G) WT (gray bars) or tailless (white bars) ICOSL and WT NOD2 were transfected
1 mg/ml MDP, or a combination of both for 24 hr. Significance comparisons are b
WT versus tailless ICOSL-transfected cells treated with the same stimuli indicate
(H) WT ICOSL or ICOSL mutants and WT NOD2 were transfected into HeLa c
(right) 10 mg/ml ICOS and 1 mg/ml MDP for 24 hr. Significance compared to (left) I
(G and H) The data are represented as IL-6 secretion in triplicate + SEM (represen
whole cell lysate. **p < 0.01; ***p < 0.001; y, p < 1x104; yy, p < 1 3 105.to interrogate, two separate cohorts of 100 and 98 individuals were recruited
for NOD2 and TLR2 dose-response studies, and NOD2 and TLR synergy
studies in MDDC, respectively. Genotyping for polymorphisms was performed
by TaqMan SNP genotyping (Applied Biosystems) or Sequenom platform
(Sequenom). For association studies, a total of 2,724 subjects were enrolled,
including 1512 CD cases (542 ileal, 705 ileocolonic, and 265 colonic cases)
and 1,212 healthy controls. CD patients were diagnosed by clinical, endo-
scopic, radiologic and histologic criteria. Medical histories were collected
with the validated NIDDK IBD Genetics Consortium phenotype forms (Nguyen
et al., 2006).
Primary Human Cell Culture
Monocytes were purified and differentiated toMDDCs as in Hedl and Abraham
(2012). T cells were isolated with CD4 selection (Miltenyi Biotec) and activated
with platebound anti-CD3 (5 mg/mL) and anti-CD28 (1 mg/mL) (R&D Systems)
for 5 days. Activation was confirmed by proliferation and upregulation of the
activation markers CD25 and CD69. Intestinal lamina propria cells were iso-
lated from colonic resection specimens from uninvolved intestine in five nonin-
flammatory bowel disease patients undergoing surgery for diverticular disease
or colon cancer. Briefly, intestinal resections were washed and then digested
(RPMI containing 0.2mMEDTA, beta-mercaptoethanol) in a 37C shaker to re-
move epithelial cells. Epithelial cells and intraepithelial lymphocytes were dis-
carded and intestines were washed, cut into 1mm2 pieces, and incubated in a
buffer consisting of RPMI, 75 mg/ml collagenase Type VIII, DNase (Sigma-
Aldrich) and HEPES for 45min in a 37C shaker. The cells were filtered through
a 40 mm filter, selected on a ficoll gradient, washed, and analyzed by FACS.
MDDCs and HL-60 Cell Stimulation
MDDCs or HL-60 human myeloid cells were treated with MDP (Bachem),
Pam3Cys, lipid A (Peptides International), flagellin, CL097, CpG, poly I:C
(Invivogen), E. coli LPS (Sigma-Aldrich), ICOS, and ICOSL (R&D Systems).
Supernatants were assayed for TNF-a, IL-8, IL-10 (BD Biosciences), IL-23,
or IL-1b (eBioscience) by ELISA.
Transfection of Small Interfering RNAs
We transfected 300 nM scrambled or ON-TARGETplus SMARTpool siRNA
against ICOSL, ICOS, PKCa, or PKCb (Dharmacon) (four pooled siRNAs for
each gene) into MDDCs as in Hedl and Abraham, (2012).
Constructions and Transfection of ICOSL Mutant Vectors
ICOSL tailless (generated by inserting a stop codon), S285A, S293A, S285A
and S293A, R278A, R280A, and R278A and R280A mutants were generated
through site-directed mutagenesis (QuikChange Lightning kit; Agilent Tech-
nologies) of WT ICOSL cDNA clone in pReceiver vector (GeneCopoeia), and
the mutations were confirmed by sequencing. HeLa cells were transiently
transfected by Lipofectamine (Invitrogen) with 4 mg WT or mutant ICOSL
vectors or empty vector ± 50 ng WT NOD2 in pCDNA.3. Twenty-four hr after
transfection, cells were assayed for ICOSL surface expression or stimulated
as indicated.
Protein Detection
Phosphoproteins were detected with Alexa Fluor 647-labeled phospho-ERK,
phospho-p38, phospho-JNK, phospho-Jun, phospho-Akt, phospho-p70-S6K,
phospho-IkBa (Cell Signaling), and phospho-PKC (Santa Cruz Biotechnology)were immunoprecipitatedwith anti-ICOSL antibody. Associated phospho-Jun
as the loading control.
our hr later, cells were stimulated for 15 min with 10 mg/ml ICOSL. Top shows
ized data are represented as the fold phosphoprotein induction normalized to
S-treated, WT ICOSL transfected cells.
into HeLa cells. Twenty-four hr later, cells were stimulated with 10 mg/ml ICOS,
etween single versus combined treatment conditions as indicated, or between
d above white bars.
ells. Twenty-four hr later, cells were stimulated with (left) 10 mg/ml ICOS or
COS- or (right) ICOS- and MDP-treated, WT ICOSL-transfected cells is shown.
tative of three independent experiments). scr, scrambled, Tx, treatment, WCL,
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Figure 7. The rs7282490 Risk G Allele in the ICOSLG Region Is Associated with Decreased Basal and NOD2-Induced ICOSL Expression,
Decreased ERK Activation, and an Increased Likelihood of Ileal Crohn’s Disease
(A–C) MDDCs from rs7282490 AA, GA, or GG carriers (n = 8 for each group) were left untreated or stimulated with 100 mg/ml MDP for (A) 4 hr or (B) 12 hr.
Summarized data are represented as ICOSL (A) mRNA expression (expressed as the change in CT values from duplicate samples normalized to GAPDH and
represented as a linear scale) + SEM or (B) protein expression, with average MFI values indicated above bars (right). (B) Representative flow cytometry plots of
ICOSL expression with MFI values are as indicated (left). (C) Summarized data are represented as fold NOD2-induced ICOSL mRNA and protein expression
relative to untreated cells + SEM.
(D) MDDC from rs7282490 AA or GG carriers (n = 7 for each group) were stimulated for 15min with 10 mg/ml ICOS or 1 mg/ml MDP, either alone or in combination.
Left shows representative flow cytometry plots of phospho-ERK with MFI values as indicated. Right shows summarized data are represented as the fold
phospho-ERK induction normalized to untreated cells + SEM.
(E) Top shows that the ICOSLG rs7282490 polymorphism was stratified on CD location with the allelic inheritance model or recessive inheritance model.
Bottom shows a control, risk allele frequencies ofNOD2CD-risk polymorphismswere stratified onCD locationwith allelic inheritancemodel.D, change; OR, odds
ratio. *p < 0.05; **p < 0.01; y, p < 1x104; yy, p < 1 3 105.
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(BDBiosciences). ICOSwasmeasuredwithAPC-labeledmouseanti-ICOSanti-
body (R&D Systems, clone 669222) by flow cytometry or with mouse anti-ICOS
antibody (Santa Cruz, clone ANC6C6-A3) by immunoblot.
ICOSL was immunoprecipitated from HL-60 or transfected HeLa lysates
with anti-ICOSL antibody (Abcam)-bound to protein A Sepharose (Upstate
Biotechnology). PKC-mediated phosphorylation was visualized with an anti-
PKC-substrate antibody (Cell Signaling) and ICOSL-associated proteins
were examined with antibodies recognizing RACK1, PKCb (R&D Systems),
JNK, phospho-Jun, or phospho-PKCb (Cell Signaling). GAPDH antibody744 Immunity 40, 734–746, May 15, 2014 ª2014 Elsevier Inc.(EMD Biosciences) and ICOSL antibody (Abcam) were used to assess equal
loading.
mRNA Expression Analysis
Quantitative PCR was performed as in Hedl and Abraham, (2011a). Samples
were normalized to GAPDH. Primers are available upon request.
Statistical Analysis
Association of ICOSL and NOD2 variants with disease location in CD patients
was tested under the allelic and recessive genetic inheritance models with the
Immunity
ICOSL Amplifies Innate Receptor-Mediated SignalingChi-square test as implemented in PLINK (Purcell et al., 2007). Significance for
experimental studies was assessed with two-tailed t test. p < 0.05 was consid-
ered significant.
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